Profile data is unavailable for this security.
About the company
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
- Revenue in JPY (TTM)4.46tn
- Net income in JPY112.93bn
- Incorporated1925
- Employees47.46k
- LocationTakeda Pharmaceutical Co Ltd4F, 2-1-1, Nihombashihon-choCHUO-KU 103-8668JapanJPN
- Phone+81 332782111
- Fax+81 332782000
- Websitehttps://www.takeda.com/jp
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. | 490.32bn | 6.65bn | 6.23tn | 2.23k | 1,348.37 | 173.82 | 408.01 | 12.70 | 0.2288 | 0.2288 | 24.38 | 1.77 | 0.7089 | 6.83 | 7.08 | 1,439,493.00 | 0.962 | -20.07 | 1.39 | -25.51 | 83.90 | 84.18 | 1.36 | -55.19 | 2.49 | 1.03 | 0.9146 | -- | 22.97 | 59.21 | 36.82 | -- | -24.55 | -- |
| Sun Pharmaceutical Industries Ltd | 958.14bn | 176.98bn | 6.94tn | 43.00k | 39.24 | -- | 30.69 | 7.24 | 43.70 | 45.45 | 236.59 | -- | -- | -- | -- | 13,211,420.00 | -- | 9.09 | -- | 12.38 | 79.97 | 73.38 | 18.62 | 16.07 | -- | -- | -- | 39.34 | 8.42 | 9.87 | 14.12 | 23.76 | 6.66 | 31.95 |
| Haleon PLC | -20.81tn | -20.81tn | 7.54tn | 24.00k | -- | 2.29 | -- | -- | -- | -- | -- | 1.77 | -- | -- | -- | -- | -- | 3.67 | -- | 4.23 | -- | 62.28 | -- | 11.97 | 0.6327 | -- | 0.3464 | 218.58 | -0.6105 | 5.78 | 37.46 | 17.10 | 5.53 | -- |
| CSL Ltd | 2.36tn | 456.19bn | 8.00tn | 32.07k | 17.56 | 2.72 | 12.67 | 3.38 | 8.67 | 8.67 | 44.90 | 56.04 | 0.4019 | 1.20 | 5.16 | 680,888.80 | 8.10 | 8.58 | 9.87 | 10.61 | 51.93 | 52.91 | 20.16 | 19.71 | 1.12 | 10.01 | 0.3494 | 47.42 | 5.12 | 11.20 | 13.63 | 7.38 | -6.11 | 7.95 |
| Bayer AG | 8.32tn | -35.90bn | 8.14tn | 88.50k | -- | 1.52 | 13.20 | 0.9787 | -0.2015 | -0.2015 | 46.69 | 30.11 | 0.4344 | 1.58 | 4.52 | 494,165.80 | -0.1639 | -2.66 | -0.2205 | -3.61 | 56.35 | 57.98 | -0.3772 | -6.88 | 0.7096 | 2.33 | 0.5717 | -- | -2.16 | 1.37 | 13.23 | -- | 0.9479 | -47.66 |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 685.77bn | 165.30bn | 8.29tn | 20.24k | 50.12 | 6.55 | -- | 12.09 | 1.17 | 1.17 | 4.84 | 8.97 | 0.5312 | 1.71 | 5.75 | 1,530,951.00 | 12.82 | 12.67 | 14.40 | 14.00 | 85.49 | 85.64 | 24.14 | 20.06 | 6.20 | -- | 0.0014 | 23.84 | 22.63 | 3.74 | 47.28 | 3.53 | 28.53 | 4.60 |
| Zoetis Inc | 1.45tn | 408.29bn | 8.46tn | 13.80k | 20.86 | -- | 18.04 | 5.85 | 6.02 | 6.02 | 21.33 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 71.87 | 70.67 | 28.23 | 27.03 | -- | 19.35 | -- | -- | 2.28 | 7.24 | 7.52 | 10.29 | -- | 20.11 |
| Takeda Pharmaceutical Co Ltd | 4.46tn | 112.93bn | 8.92tn | 47.46k | 77.62 | 1.16 | 10.37 | 2.00 | 72.26 | 72.26 | 2,834.46 | 4,838.54 | 0.2926 | 1.17 | 6.17 | 94,080,250.00 | 0.7418 | 1.71 | 0.8772 | 2.04 | 65.33 | 67.66 | 2.54 | 5.99 | 0.6548 | 3.49 | 0.3884 | 123.75 | 7.45 | 6.84 | -25.08 | 19.53 | 9.82 | 1.72 |
| UCB SA | 1.24tn | 241.51bn | 9.65tn | 9.38k | 39.89 | 5.37 | 27.84 | 7.77 | 6.86 | 6.86 | 35.27 | 50.96 | 0.4174 | 1.46 | 4.26 | 730,219.70 | 8.12 | 4.98 | 10.21 | 6.20 | 73.38 | 71.71 | 19.45 | 13.00 | 1.01 | 11.23 | 0.2291 | 34.22 | 17.14 | 4.60 | 210.50 | 6.16 | 1.84 | 2.31 |
| Merck KGaA | 3.86tn | 535.79bn | 9.89tn | 62.35k | 18.46 | 1.88 | 11.20 | 2.56 | 6.79 | 6.79 | 48.92 | 66.55 | 0.4209 | 1.97 | 5.04 | 340,025.90 | 5.85 | 6.04 | 7.23 | 7.70 | 58.69 | 61.15 | 13.91 | 13.80 | 0.9686 | 18.28 | 0.2943 | 9.11 | 0.7765 | 5.55 | -1.66 | 16.54 | 16.42 | 11.10 |
Data as of Feb 13 2026. Currency figures normalised to Takeda Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
25.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 08 Jan 2026 | 69.94m | 4.40% |
| BlackRock Fund Advisorsas of 15 Apr 2025 | 59.40m | 3.73% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 58.63m | 3.69% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 15 Sep 2025 | 49.61m | 3.12% |
| BlackRock Japan Co. Ltd.as of 15 Apr 2025 | 36.01m | 2.26% |
| Amova Asset Management Co., Ltd.as of 15 Sep 2025 | 34.23m | 2.15% |
| Daiwa Asset Management Co. Ltd.as of 30 Dec 2025 | 31.26m | 1.97% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 24.56m | 1.54% |
| Geode Capital Management LLCas of 05 Feb 2026 | 23.33m | 1.47% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 08 Jan 2026 | 18.01m | 1.13% |
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
